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ABSTRACT
miRNAs are 20–22 nt long post-transcriptional reg-
ulators in metazoan cells that repress protein ex-
pression from their target mRNAs. These tiny reg-
ulatory RNAs follow tissue and cell-type specific ex-
pression pattern, aberrations of which are associ-
ated with various diseases. miR-122 is a liver-specific
anti-proliferative miRNA that, we found, can be trans-
ferred via exosomes between human hepatoma cells,
Huh7 and HepG2, grown in co-culture. Exosomal
miR-122, expressed and released by Huh7 cells and
taken by miR-122 deficient HepG2 cells, was found
to be effective in repression of target mRNAs and to
reduce growth and proliferation of recipient HepG2
cells. Interestingly, in a reciprocal process, HepG2
secretes Insulin-like Growth Factor 1 (IGF1) that de-
creases miR-122 expression in Huh7 cells. Our ob-
servations suggest existence of a reciprocal inter-
action between two different hepatic cells with dis-
tinct miR-122 expression profiles. This interaction
is mediated via intercellular exosome-mediated miR-
122 transfer and countered by a reciprocal IGF1-
dependent anti-miR-122 signal. According to our
data, human hepatoma cells use IGF1 to prevent in-
tercellular exosomal transfer of miR-122 to ensure its
own proliferation by preventing expression of growth
retarding miR-122 in neighbouring cells.
INTRODUCTION
miRNAs are ∼22 nucleotide long non-coding RNA
molecules which act as key post-transcriptional regulators
of gene expression in metazoan animals and plants. miR-
NAs repress gene expression by binding to complemen-
tary sequences in the 3’untranslated region (UTR) of target
mRNAs, thereby inhibiting translation and inducing dead-
enylation and degradation of target mRNAs (1). miRNA
biogenesis is regulated both at transcriptional and post-
transcriptional level and misregulation of these processes
leads to various human pathologies, including cancer (2).
Expression profiles of miRNAs revealed a cancer-type spe-
cific signature of miRNA expression that differ with disease
progression stages (3–6). Among the miRNAs expressed in
animal cells, some miRNAs can act as tumour suppressors
while increased expression of few other miRNAs can cause
transformation of cells and cancer in mouse models (7,8).
In a tumour microenvironment, cancer cells interact
with normal non-transformed cells and compete for re-
sources and factors in their environment. Interestingly, non-
tranformed cells may have an inhibitory role against the
growth and proliferation of transformed tumour cells. Pre-
viously, it was demonstrated that Normal breast epithelial
cells and their Conditioned Media (CM) could inhibit pro-
liferation of a variety of breast cancer cell lines (9).
Recently, it has been shown that miR-143, a tumour sup-
pressor miRNA, released from normal prostrate cells can
transfer growth inhibitory signals to prostrate cancer cells
(10). Thus the normal cells secrete anti-proliferative miR-
NAs in an attempt to maintain normal miRNA homeosta-
sis; however the abnormal cancer cells finally circumvent
this inhibitory effect resulting in expansion of the tumour.
miRNAs have been detected in various human body
fluids including peripheral blood plasma, saliva, serum
and milk (11). Tumour associated miRNAs were higher in
serum of lymphoma patients as compared to healthy con-
trols (12) while miRNA content of mast cell derived exo-
somes are transferable to other human andmousemast cells
(13). Epstein-Barr virus (EBV) infected B cells secrete EBV
encoded miRNAs in exosomes which repress immunoregu-
latory genes (14). Exosomal miRNAs are released through
a ceramide-dependent secretorymachinery and the secreted
miRNAs are transferable and functional in the recipient
cells (15). In a recent study, exosome mediated delivery of
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oncogenic miRNAs and regulation of invasiveness of breast
cancer cells by macrophages has been reported (16). THP-
1-derived microvesicles that can enter and deliver miR-150
into human HMEC-1 cells reduced c-Myc expression and
enhanced cell migration of HMEC-1 cells (17). Exosomal
miRNA transfer from T cells to Antigen Presenting Cells
in immune synapses was also documented (18). These and
other reports indicate that cells communicate with each
other by secreting miRNA laden vesicles that serve as in-
tercellular messengers.
miR-122 has been characterized for its multiple roles in
liver physiology, metabolism and in modulation of hepatitis
C virus replication. It is a liver-specific miRNA represent-
ing 70% of the liver miRNA population (19,20). Notably,
its loss or downregulation has been associated with hu-
man and rodent hetatocellular carcinoma (HCC) develop-
ment and progression (21–27). In this study, we have docu-
mented exosome mediated transfer of miR-122 between co-
cultured human hepatoma cells. HepG2 and Huh7 are two
human hepatic cell lines that are well explored to study liver
function and metabolism. HepG2 cells have highly reduced
levels of miR-122 whereas Huh7 cells express this hepatic
miRNA in high amounts (28,29). miR-122 transfer from
Huh7 to HepG2 can change the expression of various miR-
122 regulated genes in the recipient HepG2. There is a con-
comitant downregulation of miR-122 expression in Huh7
cells mediated by HepG2 secreted Insulin-like Growth Fac-
tor 1 (IGF1). HepG2 cells overcome the restorative effect
exerted by the transferredmiR-122 by secreting IGF1which
in turn inhibits miR-122 biogenesis in neighbouring cells.
This reciprocal effect exerted by HepG2 on miR-122 pro-
ducing neighbouring cells may a indicate a strategy that
hepatic cancer cells adopt to modulate their microenviron-
ment to their benefit and proliferation.
MATERIALS AND METHODS
Cell culture
Human HCC cell lines HepG2 and Huh7 were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-
BRL) supplemented with 10% fetal bovine serum (FBS;
GIBCO-BRL) and Penicillin Streptomycin (1X) antibiotics
(GIBCO).
Plasmid constructs
The RL reporters (Renilla luciferase) were previously de-
scribed (30,31). Details of plasmids are available in Supple-
mentary Table S1.
siControl, siSMNaseII, siIGF1R and siIGF1 were used
for transfection at 100 pmoles per well of a confluent
six-well plate. miR-122 and let-7a mimic and anti-let-7a
and anti-miR-122 were purchased from Ambion and was
used at 100 pmoles to transfect cells per well of a six-well
plate. Cells were differentially transfected for fluorescence-
activated cellsorting (FACS) and microscopy using pcI-
neoGFP and DsRed Monomer (Clontech) plasmids. To
exogenously express miR-122, cells were transfected with
pmiR122 plasmid. For transfections, 1 g of each of the
plasmids was used for transfection of 106 cells in a 10 cm2
well. Details of plasmid and siRNA constructs are given as
Supplementary Tables S1 and S2.
Luciferase assays
For luciferase assays 106 cells in a 10 cm2 well were trans-
fected with either RL-con or RL-per-miR-122 plasmids
(above) in parallel sets. To detect fold repression in HepG2,
106 cells in a 10 cm2 well were transfected with 150 ng of
each of the plasmids. Normalisation was done with a Fire-
fly (FF) luciferase construct which was co-transfected along
with the RL constructs (1 g for 1 × 106 cells). After 24
h of transfection, cells were co-cultured with Huh7 and
HepG2 cells in a 24 well-plate at desired Huh7:HepG2 ra-
tios. These were then co-cultured for 48 h. After that cells
were lysed with 1 X Passive Lysis Buffer (Promega). Re-
nilla (RL) and Firefly (FL) activities were measured using a
Dual-Luciferase Assay Kit (Promega) following the suppli-
ers protocol on a VICTOR X3 Plate Reader with injectors
(Perkin Elmer). Mean Fold Repression was calculated by
dividing the FF normalized RL-Con value with that of FF-
normalized RL-per-miR-122 value. Relative fold repression
was calculated by taking the control mean fold repression
as 1. For co-culture-based luciferase assays in HepG2, cells
were usually co-cultured at a ratio of 40% of HepG2 to 60%
of the co-cultured cell.
To detect fold repression in Huh7, 106 Huh7 cells in a 10
cm2 well were transfected with 100 ng of RL-Con and RL-
perf-miR-122. For normalisation of RL expression, cells
were co-transfected with 500 ng of the FF luciferase con-
struct and after 24 h of transfection, cells were splited and
co-cultured with other nontransfected cells at a ratio of 50%
of transfectedHuh7 and 50% of the nontransfected cell. Af-
ter 72 h, cells were lysed with 1 X Passive Lysis Buffer and
luciferase levels were detected in a Victor X3 plate reader.
All luciferase assays used in this study have been done in
triplicate. All experiments were performed minimum three
times before the SD values were calculated.
Sorting of co-cultured and artificially mixed HepG2 and
Huh7 populations
For FACS analysis, co-culturedHepG2 andHuh7 cells were
used. HepG2 cells (5× 105) were added to equal number of
Huh7 cells in a 20 cm2 dish and co-cultured for 48 h. As a
control 5 × 105 HepG2 cells and 5 × 105 Huh7 cells were
seeded separately in 10 cm2 dishes. Seeding was done such
that cells attained 100% confluencies after 48 h. After 48 h,
co-cultured cells were trypsinized and collected for FACS
analysis. HepG2 andHuh7 cells seeded separately were also
similarly collected and mixed together to comprise the arti-
ficially mixed cell population which was used as a control to
negate any false positive signals during the sorting process.
For sorting, co-cultured and artificiallymixed cells were col-
lected as described above. Cells were resuspended in FACS-
buffer (PBS with 3% FBS) to 2 × 106 cells/ml. Cells were
then subjected to sorting in a BD FACS Aria II sorter and
sorted cells were collected in FBS coated FACS tubes con-
taining FACS buffer.
To measure cell growth rate, co-cultured and artificially
mixed cells were collected by trypsinization at specific time
7172 Nucleic Acids Research, 2014, Vol. 42, No. 11
points. Cells were then fixed with 4% paraformaldehyde for
30min. Fixed cells were kept in 75% ethanol. Just before the
sorting experiment, cells were rehydrated in 1 X PBS for 30
min. In a population the percentage of Green Fluorescent
Protein (GFP) and DsRed positive cells were estimated by
FACS analysis. Relative growth rate wasmeasured by divid-
ing the percentage of green (GFP)/Red (DsRed) cells in the
co-cultured set with the percentage in the control set.
Cell transfections
All transfections (plasmids, siRNAs and 2’-O-methyl oli-
gos) were performed using Lipofectamine 2000 (Invitrogen)
following manufacturer’s instructions.
Quantitative estimation of mRNA and miRNA levels
RNA was extracted by using the TRIzol reagent according
to themanufacturer’s protocol (Invitrogen). Real-time anal-
yses by two-step RT-qPCR was performed for quantifica-
tion of miRNA and mRNA levels. All RT-qPCRs were per-
formed on a 7500 REAL TIME PCR SYSTEM (Applied
Biosystems). mRNA real-time quantification was generally
performed in a two-step format using Eurogentec Reverse
Transcriptase Core Kit andMESAGREEN qPCRMaster
Mix Plus for SYBR Assay with Low Rox kit from Euro-
gentec following the suppliers’ protocols. The comparative
Ct method which typically included normalisation by 18S
rRNA levels for each sample was used for relative quantifi-
cation. Details of mRNA gene specific primers are given as
Supplementary Table S3.
Quantification of miRNA levels was done using Applied
Biosystem TaqMan R© chemistry based miRNA assay sys-
tem.Assays were performedwith 25 ng of cellular RNAand
100 ng of exosomal RNA unless specified otherwise, using
specific primers for humanmiR-122, miR-24 and let-7a (as-
say ID 000445, 002440, 000377, respectively). U6 snRNA
(assay ID 001973) was used as an endogenous control.
One-third of the reverse transcription mix was subjected to
PCR amplification with TaqMan R©Universal PCRMaster
Mix No AmpErase (Applied Biosystems) and the respec-
tive TaqMan R© reagents for target miRNA. The RT reac-
tion condition was 16◦C, 30min; 42◦C, 30min; 85◦C, 5min;
4◦C, ∝. The PCR condition was 95◦C, 5 min; 95◦C, 15 s;
60◦C, 1 min; for 40 cycles.
Samples were analysed in triplicates from minimum
two biological replicates. The concentrations of intra and
extracellular miRNAs were calculated based on their
normalized Ct values. The Ct method for relative
quantitation (RQ) of gene expression was used and rel-
ative quantification was done using the equation 2−Ct
(as per ‘Guide to Performing Relative Quantitation of
Gene Expression Using Real-Time Quantitative PCR’
obtained from the Applied Biosystems website, http:
//www3.appliedbiosystems.com/cms/groups/mcb support/
documents/generaldocuments/cms 042380.pdf).
Exosome isolation and experiments with CM
For all exosome-related experiments, exosome depleted
FCS was used. Exosome depleted FCS was either com-
mercially obtained (System Biosciences Catalog no. EXO-
FBS-250A-1) or prepared by ultracentrifugation of the FCS
used at 110,000×g for 5 h. For exosome isolation cells were
grown in media made from exosome depleted FCS. The su-
pernatant CM from two 60 cm2 plates, having 6× 106 donor
cells (Huh7 orHepG2) each were taken. The CMswere cen-
trifuged first at 300×g for 10min, then at 2000×g for 15min
followed by centrifugation at 10,000×g for 30 min. All cen-
trifugations were done at 4◦C. The CM was then filtered
through a 0.22 m filter unit. This was then centrifuged
at 100,000×g for 90 min at 4◦C. After centrifugation, the
supernatant was discarded. The pellet was resuspended in
media and added back to recipient cells (HepG2 or Huh7)
in a 24-well plate format such that 2 × 105 recipient cells
received the exosomes from 1 × 106 donor cells. For CM-
based assays the same ratio was followed with CM from
106 cells being added to 2 × 105 cells. For incubation times
greater than 24 h, media was replaced with fresh CM after
every 24 h. For the isolation of miR-122, anti-miR-122 and
anti-let7a carrying exosomes, 1 × 106 cells were transfected
and 24 h after transfection, the cells were reseeded onto a
60 cm2 plate. Cells were grown for 48–72 h and exosomes
isolated from the CM of these cells.
For the experiment in Figure 1J, the supernatant from
Huh7 cells was centrifuged to clear cellular debris and
this constituted the Huh7 CM. This was then further cen-
trifuged in a centricon with a molecular weight cutoff of
100 kDa such that constituents having molecular weight of
<100 kDawere filtered out and those which were>100 kDa
were retained. The latter was then filter sterilized and added
to HepG2 cells.
For the experiment described in Figure 1K, CM from two
60 cm2 plates, after being passed through the 0.22 m filter
was loaded on to a 30% sucrose cushion. This was ultracen-
trifuged at 100 000xg for 90 min at 4◦C. The medium above
the sucrose cushion was discarded leaving behind a narrow
layer of medium with the exosomes at the interface. 1XPBS
was added and the separated exosomes were washed at 4◦C
for 90 min at 100 000xg. The pellet was resuspended in 200
l of 1X Passive Lysis Buffer, half of which was used for
western analysis and the remaining half was used for miR-
122 analysis by real-time quantification.
Incubation with growth factors
Various growth factors were purchased from Invitrogen.
They are Recombinant Human IGF-1 (Cat no. PHG0078),
Recombinant Human TGF-1 (Cat no. PHG9214), Re-
combinant Human HGF (Cat No. PHG0254), Recombi-
nant Human IGF-II (Cat no. PHG0084), Recombinant
Human EGF (Cat no. PHG0315).
For Figure 5B, cells transfected with RL reporters were
incubated overnight with media (DMEM) containing 0.1%
FCS. This was replaced the next day with DMEM con-
taining indicated concentrations of various growth factors.
Cells were lysed after 24 h. For all other experiments with
growth factors, indicated concentrations of the factors were
added to Huh7 CM which had been depleted for miR-
122 containing exosomes by centrifuging at 100,000 x g for
90 min. Incubations were done for 72 h with addition of
freshmedia (exosome depleted) with IGF1 once in between.
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Figure 1. Huh7 cells can transfer miR-122 to neighbouring HepG2 cells in co-culture. (A) Schemes of RL reporters used for miR-122 activity analysis in
hepatic cells. (B, C) Effects of variable cell-to-cell ratios of Huh7 and HepG2 in co-culture on miR-122 activity transfer to HepG2 cells. Normalized RL
values for individual reporter transfectedHepG2 cells co-cultured either with 40% of non-transfectedHepG2 (control) orHuh7were plotted (B).Mean fold
repression was estimated by dividing the normalized RL levels in RL-con and RL-per-miR-122 expressing cells with changing Huh7 to HepG2 cell number
ratios. Experiments were done in triplicate (C). Data shown are the mean ±SEM. Relative fold repression was determined by setting the repression level of
control as 1. (D) Flowchart of co-culture followed by sorting experiment. GFP positive HepG2 cells were co-cultured with DsRed and miR-122 expressing
Huh7 cells and after 48 h, cells were FACS sorted and were used for further analysis. (E) Let-7a and miR-122 levels in sorted HepG2 cells obtained as
described inD. Relative miRNA levels were measured by quantitative RT-PCR.Normalization was done byU6 snRNA.HepG2 cells, grown separately but
pre-mixed with Huh7 immediately before the sorting, were used as control. Data shown are the mean ±SEM from three separate experiments performed
in triplicate. (F) Relative level of pre-miR-122 in Huh7 and HepG2 cells. Same amount of RNA isolated from these cells was used for analysis. 18S rRNA
was taken as the internal control and Ct ( = Ct sample- Ct 18S) values were plotted. (G) Relative levels of pre-miR-122 were detected in Sorted HepG2
cells obtained as described in D.Normalization of qPCR data was done by 18S rRNA. Data shown are the mean ±SEM from three separate experiments
performed in triplicate (lower panel). (H) Cyclin G1 and p53 expression in sorted HepG2 cells both in control or co-cultured with Huh7 for 48 h. -actin
was used as loading control. (I) Relative expression of miR-122 target genes in sorted HepG2 cells measured by real-time quantitative PCR. Normalization
of qPCR data was done by 18S rRNA. Data shown are the mean ±SEM from three separate experiments performed in triplicate. (J) Repression of miR-
122 reporter in HepG2 cells treated either with Huh7 CM, or >100 KDa cutoff fraction of Huh7 CM, or with exosomes isolated from Huh7 cells (top).
miR-122 levels are detected in the bottom panel. U6 serves as loading control. (K) Immunoblotting of Alix and CD63 and quantification of miR-122 in
exosomes secreted by Huh7 cells treated with increasing amounts of the neutral Sphingomyelinase II inhibitor GW4869. (L) Levels of miR-122-mediated
repression in reporter transfected and Huh7 co-cultured HepG2 cells in presence and absence of GW4869. (M) miR-122-mediated repression in HepG2
cells co-cultured with Huh7 cells transfected with a control siRNA or siRNA against neutral Sphingomyelinase II. Data are presented as means ±SEM in
all results obtained from multiple experiments (n = 3) when ns: non-significant, *P < 0.05, **P < 0.01 and ***P < 0.001. All luciferase experiments have
been conducted in triplicate. For data presented in panels E, F, G, I and K the Ct method for RQ of gene expression was used and generated using the
equation 2−Ct. P values were determined by paired t test.
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For antibody blocking experiment described in Figure 5H,
indicated concentrations of antibodies were added for 1
h at 37◦C to HepG2 CM. Following this pre-incubation,
the antigen–antibody mixture was added to reporter trans-
fected Huh7 cells.
Statistical analysis
All graphs and statistical analyses were generated inGraph-
Pad Prism 5.00 (GraphPad, San Diego, CA, USA). Non-
parametric unpaired t-test and paired t test were used for
analysis, and P values were determined. Error bars indicate
mean ±SEM.
RESULTS
Intercellular transfer ofmiR-122 between human hepatic cells
To determine the importance of crosstalk between liver cells
in the homeostasis of miRNA expression, we used human
hepatoma cells HepG2 and Huh7 for our study. Despite its
hepatic origin, HepG2 has highly reduced levels of miR-
122 whereas Huh7 expresses this miRNA in high amounts
(28,29). We wanted to see if miR-122 fromHuh7 cells could
be transferred toHepG2 cells in a co-culturemodel. HepG2
cells transfected with a plasmid encoding RL reporter with
one perfect miR-122 binding site were co-cultured with
Huh7 cells or, as a control, with non-transfected HepG2
cells. We documented increased repression of miR-122 re-
porter inHepG2 cells co-culturedwithHuh7 cells where the
extent of repression was determined byHepG2 toHuh7 cell
ratio in the co-culture (Figure 1A–C).
To determine whether repression of miR-122 reporter in
HepG2 is due to an actual transfer of miRNA between the
co-cultured cells or due to an induction of miR-122 ex-
pression in HepG2 by Huh7 cells, GFP expressing HepG2
cells were co-cultured with DsRed expressing Huh7 cells for
48 h before they were sorted to GFP and dsRed positive
cell pools (Figure 1D and Supplementary Figure S1). As a
control, separately grown GFP positive HepG2 and DsRed
positive Huh7 were mixed together just before sorting and
also separated to individual pools. Relative quantification
of the miR-122 levels in the sorted HepG2 cells that other-
wise have low levels ofmaturemiR-122 indicated a 9-fold in-
crease of mature miR-122 level upon co-culture with Huh7
cells while the let-7a miRNA level in sorted HepG2 cells re-
mained unchanged (Figure 1D and E). Interestingly, when
measured, no corresponding increase in miR-122 precursor
was detected in the sorted HepG2 cells (Figure 1F and G).
These results indicate direct transfer of mature miR-122 to
HepG2 cells grown in a co-culture with Huh7 cells.
Cyclin G1 is a target of miR-122. Previously, it was re-
ported that miR-122 expression in HepG2 cells decreased
Cyclin G1 expression and was accompanied by an increase
in p53 protein (29). Upon co-culture with Huh7, western
blotting of sorted HepG2 cells revealed a reduced level of
Cyclin G1 protein as compared to control. This was as-
sociated with an increase in the p53 protein level (Figure
1H). Consequent real-time quantification of various miR-
122 target mRNAs (32) such asCAT1 (Solute Carrier Fam-
ily 7 Member 1/Cationic Amino Acid Transporter 1), Al-
dolase (Aldolase A), GTF2B (General Transcription Facor
IIB) and GYS1 (Glycogen Synthase 1) revealed a decrease
in their expression in HepG2 cells co-cultured with Huh7
cells as compared to control (Figure 1I).
For intercellular transfer of miR-122 in hepatic cells, in-
tercellular contacts are not required. Incubation of reporter
transfected HepG2 cells with CM from Huh7 cells for 24
h also resulted in an increase in fold repression of miR-
122 reporter in HepG2 cells (Figure 1J). This property of
Huh7 CM was retained in the ≥100 KDa cutoff fraction.
Northern analysis confirmed the transfer of mature miR-
122 toHepG2 cells when incubated either withHuh7CMor
with its≥100KDa cutoff fraction. Exosomes, isolated from
the ≥100 KDa cutoff fraction of Huh7 CM when added to
HepG2 cells, were able to transfer miR-122 to the recipi-
ent cells. These results suggest transfer of mature form of
miR-122 from Huh7 to HepG2 cells, possibly via exosomal
vesicles (Figure 1J and Supplementary Figure S2). Secre-
tion of miRNA containing exosomes is regulated by neutral
Sphigomyelinase II (nSMNase II) gene in mammalian cells
(15,33). This protein is known to hydrolyze sphingomyelins
to generate ceramides and trigger the budding of exosomes.
GW4869 is a specific inhibitor for neutral Sphingomyeli-
nase II and decreases exosome secretion inmammalian cells
(15). The secretion of miR-122 containing exosomes from
Huh7 was found to be inhibited with increasing concentra-
tions of GW4869, which also lowers the tetraspanin CD63
(34,35) and ALIX, two mammalian exosomal marker pro-
teins (Figure 1K). These results are consistent with exo-
somes being the probable vehicle for intercellular miR-122
delivery. Confirming the importance of exosomal delivery
in intercellular miR-122 transfer, the increase in miR-122
activity in HepG2 cells upon co-culture with Huh7 was pre-
vented in the presence of GW4869 (Figure 1L). The no-
tion that exosomal export of miRNA plays the key role in
transfer of miR-122 from Huh7 to HepG2 cells was fur-
ther confirmed when treatment of Huh7 cells with siRNAs
against nSMNase II resulted in inhibition of miR-122 ac-
tivity transfer from Huh7 cells to co-cultured HepG2 cells
(Figure 1M).
Both Transmission and Scanning Electron micrographs
(SEM and TEM) of Huh7 exosomes isolated by ultracen-
trifugation at 100 000xg confirmed the presence of vesi-
cles of ∼100 nm in size in exosome preparation used for
the assays (Supplementary Figure S3A). This was substan-
tiated by dynamic light scattering analysis of exosomes
that revealed bell-shaped curves with the peak of highest
intensity at diameters of ∼100 nm (Supplementary Fig-
ure S3B). Affinity purified CD63 and CD81 (36) positive
exosomes purified with Exo-FLOWTM Exosome Purifica-
tion Kit from ‘System Biosciences’ and stained with the
lipophilic Exo-FITC universal exosome stain showed shifts
in the FITC fluorescence upon binding with affinity beads
(Supplementary Figure S3C and D). This confirmed the
presence of exosomal markers in the Huh7 exosomes used
in our study. Profiling ofRNAs prepared from the exosomes
also suggested enrichment of ‘exosomes’ in the prepara-
tions either isolated by exoquick kit or by ultracentrifuga-
tion (Supplementary Figure S3E).
Imaging of exosomes by Atomic Force Microscope at
lower (Supplementary Figure S4A) and higher magnifica-
tions (Supplementary Figure S4B) revealed vesicular struc-
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tures with clusters of aggregated particles. Profile analysis
of cross sections revealed vesicle diameters of ∼100 nm.
This was further substantiated with Nanoparticle Tracking
analysis (NTA). Exosomes isolated by ultracentrifugation
at 100 000xgwere analysed at two concentrations: undiluted
and at 1/10th dilution (Supplementary Figure S4C). FTLA
analysis indicates a decrease in average diameter size with
the increase in dilution that suggests presence of aggregates
which are removedwith increasing dilution (Supplementary
Figure S4C).
Exosomal transfer of miR-122 to human HepG2 cells leads
to decreased growth and increased senescence
miR-122 overexpression in HepG2 cells decreased its’
growth rate along with an impairment in its invasion capa-
bility (29). To determine whether Huh7 co-cultured HepG2
cells show a similar phenotype, equal numbers of GFP
positive HepG2 and DsRed expressing Huh7 cells were
either co-cultured together or, as a control, seeded sepa-
rately to have comparable confluency to that of the co-
cultured cells. After 24, 48 and 72 h in culture, cells were col-
lected by trypsinization and were paraformaldehyde fixed.
As a control, separately seeded Huh7 and HepG2 cells were
trypsinized, mixed together and were fixed. These were sub-
jected to FACS analysis to score the percentage of GFP
positive and DsRed positive cells in each sample. The rel-
ative growth for each cell was calculated by dividing the
percentage of Green/Red cells in the co-cultured sets with
that in the control sets. It was observed that the growth rate
of HepG2 cells co-cultured with Huh7 decreased with time
(relative growth rate of<1). Interestingly, the growth rate of
Huh7 cells was increased in a co-culture with HepG2 (rela-
tive growth rate of >1) (Figure 2A). Thus, in a co-culture,
HepG2 and Huh7 cells affect the growth of each other in a
reciprocal manner. The effect of Huh7 on HepG2 growth is
mediated via transfer of miR-122 as inhibition of miR-122
in Huh7 resulted in impaired growth retardation of neigh-
bouring HepG2 cells (Supplementary Figure S5A).
The effect of Huh7 on HepG2 growth was further val-
idated by immunofluorescence assays which score the Pro-
liferating Cell Nuclear Antigen (PCNA) positive nuclei con-
taining cells in a population. DsRed expressingHepG2 cells
co-cultured with Huh7 cells showed decreased nuclear lo-
calization of PCNA as compared to control. However, the
effect was reversed if the Huh7 used in co-culture was pre-
transfected with anti-miR-122 oligonucleotides to block
miR-122 activity, but not in the case of anti-let-7a oligonu-
cleotides (Figure 2B and Supplementary Figure S6A).
Colony-forming ability of HepG2 cells, scored by num-
ber and size of colonies, is a marker of its proliferative po-
tential. Cells pre-treated with exosomes isolated fromHuh7
cells showed a reduced colony size compared to control.
Exosomes from anti-miR-122 treated Huh7 cells also de-
creased colony formation of recipient HepG2 cells; however
this decrease was less compared to control anti-let-7a trans-
fected Huh7 exosomes. Anti-miR-122 treatment could not
fully block the Huh7 exosomes’ effect on HepG2 colony
size, possibly due to incomplete inhibition of miR-122 in
transfected Huh7 cells (Figure 2C). This may have been be-
cause of the low transfection efficiency of Huh7. Hence, in
an effort to inducemiR-122 ‘loss of function’, anti-miR-122
and anti-let7 oligonucleotides were introduced in HepG2
cells which were then treated with Huh7 exosomes. Anti-
miR-122 treatment but not the anti-let-7a treatment re-
sulted in reversal in the reduction in colony size of HepG2
cells in the presence of Huh7 exosomes (Figure 2D). When
grown in the presence of tritiated thymidine (3H), Huh7 ex-
osome treated HepG2 showed reduced incorporation of 3H
as compared to untreated control. Treatment of cells with
exosomes isolated from miR-122 expressing HepG2 cells
also reduced 3H incorporation in target HepG2 cells, sig-
nifying a reduced proliferation of the treated cells (Figure
2E). Confirming the importance of miR-122 in this effect,
exosomes fromHuh7 cells inhibited for miR-122 did not re-
duce 3H incorporation in HepG2 cells (Figure 2F).
HepG2 cells incubated with Huh7 exosomes also exhib-
ited changes in other growth related properties. There was
an increase in cellular senescence as demonstrated by in-
creased -galactosidase staining when HepG2 cells were
treated with Huh7 exosomes. However, incubation with ex-
osomes isolated fromHuh7 cells transfected with anti-miR-
122 oligonucleotides had little effect on the senescence sta-
tus of treated HepG2 cells (Figure 2G and Supplementary
Figure S6B). Transfection of donorHuh7 cells with anti-let-
7a oligonucleotides did not affect the senescence induction
capacity of Huh7 exosomes. Therefore, transfer of miR-122
fromHuh7 toHepG2 cells results in decreased proliferation
of HepG2 cells accompanied by increased senescence.
Doxorubicin is the most widely used drug in treatment
of intermediate-advanced HCC (29,37). We attempted to
determine the doxorubicin sensitivity of HepG2 cells when
conditioned withmiR-122 containing exosomes fromHuh7
cells. Western blots revealed increased PARP and Caspase
9 cleavage in HepG2 cells treated with 50 g/ml doxoru-
bicin for 24 h in the presence of Huh7 exosomes. This was
reversed in cells treated with exosomes isolated from Huh7
cells transfected with anti-miR-122 but not with anti-let-
7a oligonucleotides. Thus treatment of HepG2 with miR-
122 containing exosomes fromHuh7 cells leads to increased
apoptosis when challenged with doxorubicin (Figure 2H).
Similar to that isolated with ultracentrifugation methods,
Huh7 exosomes isolated with Exo-FLOWTM Exosome Pu-
rificationKit from ‘SystemBiosciences’ also showed growth
retardation and drug sensitivity related effects on treated
HepG2 cells (Supplementary Figure S7).
Reciprocal inhibition of miR-122 expression in neighbouring
cells by the human HCC cell HepG2
Huh7 is a hepatoma cell that exhibits constitutive expres-
sion of miR-122 which is associated with low Cyclin G1
expression level in hepatic cells (29,38,39). Previous experi-
ments indicated that in the presence of HepG2, growth rate
of Huh7 increases (Figure 2A). Does HepG2 reduce miR-
122 in neighbouring Huh7 cells to increase their prolifera-
tion? To investigate this further, Huh7 cells expressing miR-
122 reporter were co-cultured either with non-transfected
control Huh7 cells or HepG2 cells at a ratio of 1:1. In the
presence of HepG2, there was a decrease in the relative fold
repression of miR-122 reporter in Huh7 cells as compared
to control (Figure 3A and B). Quantitative PCR indicated
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Figure 2. HepG2 cells receiving miR-122 from the donor Huh7 cells exhibit a decreased growth rate, increased senescence and increased sensitivity to
apoptosis inducing agent. (A) HepG2 cells expressing GFP were co-cultured with equal number of Huh7 cells expressing DsRed. As a control, equal
numbers of GFP-HepG2 and DsRed-Huh7 cells were cultured separately for same durations of time. Cells were collected by trypsinization and fixed and
analysed by FACS. The percentage of GFP positive and DsRed positive cells in each sample were scored and relative growth rates were plotted. Relative
growth rates were calculated by dividing the number of green (GFP) or Red (DsRed) cells in co-cultured sets by their number in the corresponding control
sets. P values were determined by paired t test between 0 and 72 h replicates. n = 4. (B) Number of PCNA positive DsRed expressing HepG2 cells in
co-culture either with HepG2 cells (control, not expressing DsRed) or with Huh7 cells (untreated or expressing anti-miR-122 or anti-let-7a oligos). PCNA
(mitosin) positive cells were then detected by indirect immunofluorescence. Data shown represents three independent slides with five fields from each slide.P
values were calculated using unpaired t test. (C) HepG2 cells treated with miR-122 containing Huh7 exosomes showed reduced growth and size of colonies.
HepG2 cells were incubated with exosomes from HepG2, Huh7, anti-miR-122 or anti-let-7a transfected Huh7, and HepG2 cells expressing miR-122, for
7 days with changes after every 48 h. The cells were then reseeded at 1 × 103 cells/cm2. After 96 h the numbers of colonies formed in each case were
counted. For each set n = 3. P values were calculated using unpaired t test. (D) Experiments were redone with HepG2 cells transfected with anti-miR-122
and anti-let7 oligonucleotides. For each set n = 3. P values were calculated using unpaired t test. (E) Tritiated thymidine incorporation in HepG2 cells,
incubated with exosomes from control HepG2, Huh7 and HepG2 expressing miR-122 and grown in presence of 3H labelled thymidine. Experiment was
done in three sets. P value was calculated by using unpaired t test. (F) Similar experiments were done with Huh7 exosomes isolated from anti-miRNA
transfected Huh7 cells. For each condition n = 3. P value was calculated by using unpaired t test. (G) Estimation of number of senescent HepG2 cells per
field. Cells were incubated with exosomes from control HepG2, Huh7, Huh7 transfected with anti-miR-122 or anti-let-7a oligos for 24 h. Cells were then
fixed and senescence assays were performed. Data represents three independent slides with five fields from each slide. P value is calculated using unpaired
t test. (H) Western analysis of cleaved PARP and Caspase 9 in HepG2 cells treated with 50 g/ml doxorubicin along with exosomes isolated from HepG2
(Control), Huh7, or anti-miR-122 and anti-let7 transfected Huh7. Exosome treatment was done for 48 h with one change after 24 h when Doxorubicin
was added. Data are presented as mean ±SEM in all results obtained from multiple experiments (minimum three) when ns: non-significant, *P < 0.05,
**P < 0.01 and ***P < 0.001.
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Figure 3. HepG2 cells secrete factors to reduce expression of miR-122 in hepatic cells. (A) Schemes of co-culture of HepG2 and Huh7 cells expressing RL
reporter for miR-122. (B) Effect of co-culture on miR-122 activity in Huh7 cells expressing RL reporter. Huh7 cells were co-cultured with non-transfected
Huh7 cells (as control) or HepG2 cells and after 72 h of co-culture, cells were lysed and luciferase activity was measured. Fold repression was estimated
by dividing the normalized RL levels in RL-con and RL-per-miR-122 expressing cells. Relative fold repression was determined by setting the repression
level of control as 1. Experiments were performed in triplicate and P value was calculated by using paired t test. (C) Levels of miR-122 in Huh7 cells grown
separately or co-cultured with HepG2 cells at ratios of 1:1. For control, equal number of HepG2 and Huh7 cells were cultured separately for the same
duration and were mixed together just before lysis. RNA was isolated from the control and co-cultured sets and real-time qPCR was performed to detect
miR-122 level change.Data represents three independent experiments with qPCR for each experiment being conducted in triplicate.P values were calculated
by paired t test. (D) RNAs obtained in experiments described in panel C were subjected to real-time quantification to estimate the relative pre-miR122
level in the control and co-cultured samples. Data represents three independent experiments with qPCR for each experiment being conducted in triplicate.
P values were calculated by paired t test. (E) Real-time qPCR analysis was done to detect the level of miR-122 in pmiR-122 plasmid transfected Huh7 in
control and HepG2 co-cultured Huh7 cells. Huh7 cells were transfected with miR-122 expressing pmiR-122 plasmid that drives pre-miR-122 expression
from a U6 promoter. Data represents four independent experiments with qPCR for each experiment being conducted in triplicate. P values were calculated
by paired t test. (F) miR-122-mediated repression in Huh7 cells transfected with RL reporter and incubated with either Huh7 (control) or HepG2 CM.
Experiments were performed in triplicate and P value was calculated by using paired t test. (G) Real-time qPCR analysis to detect miR-122 level change
in Huh7 cells treated with HepG2 CM for 72 h. As control, Huh7 cells were treated with Huh7 CM. Data represents three independent experiments with
qPCR for each experiment being conducted in triplicate. P values were calculated by paired t test. (H) Real-time analysis of pre-miR122 level in Huh7 CM
(control) and HepG2 CM treated Huh7 cells. Data represents six independent experiments with qPCR for each experiment being conducted in triplicate.
P values were calculated by paired t test. (I) QRT-PCR-based quantification of expression level changes of various hepatic nuclear factors in Huh7 cells
treated with CMs from Huh7 (control) or HepG2 cells. Data represents four independent experiments with qPCR for each experiment being conducted in
triplicate. P values were calculated by paired t test. (J) Chromatin immunoprecipitation assays followed by quantitative real-time PCR to detect the in vivo
interaction between three HNFs (HNF1, HNF3 and HNF4) and the miR-122 promoter in Huh7 cells incubated with either Huh7 CM (Control) or
HepG2 CM. Huh7 cell chromatin fragments were immunoprecipitated with antibodies for each HNF and RNA pol II. Data represents three experimental
sets with qPCR for each set being done in triplicate. Relative quantification of miR-122 promoter binding by HNFs was done by the formula 2−Ct where
Ct was calculated by subtracting the Ct for each HNF associated DNA in Huh7 CM treated set from the corresponding HepG2 CM treated set. P values
were determined by paired t test. All data is represented as mean ±SEM from multiple independent experiments. ns: non-significant, *P < 0.05, **P <
0.01 and ***P < 0.001.
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that there was a decrease in the miR-122 level in HepG2
co-cultured, as opposed to the control Huh7 cells (Figure
3C). This tells us that the observed decrease in miR-122 ac-
tivity is because of a reduced miR-122 level in Huh7 cells
co-cultured with HepG2. Real-time quantification further
revealed a similar change in the precursor form of miR-122
(pre-miR-122) in HepG2 exposed Huh7 cells, suggesting a
reduced production of miR-122 (Figure 3D). This decrease
in transcription appears to be specific for the miR-122 pro-
moter and does not depend on miR-122 identity. When
Huh7 cells were transfected with plasmids expressing pre-
miR-122 under a U6 promoter (31), there was no change
in the miR-122 level in control and HepG2 co-cultured
Huh7 cells (Figure 3E). Therefore, it may be concluded that
HepG2 cells exert a reciprocal effect on the miR-122 level
in co-cultured Huh7 cells primarily by reducing the produc-
tion of pre-miR-122.
How does HepG2 reduce pre-miR-122 expression in
Huh7 cells? Huh7 cells transfected with miR-122 reporter
showed a decreased repression even when they were incu-
bated with CM from confluent HepG2 cells (Figure 3F).
Real-time quantification in HepG2 CM treated Huh7 cells
confirmed a decreased level of cellular miR-122 (Figure
3G). HepG2 CM was also effective in downregulating pre-
miR-122 expression in Huh7 cells (Figure 3H).
In hepatic cells, expression of miR-122 is controlled pri-
marily by four liver enriched transcription factors (LETFs)
(25,36,40). We wanted to check the expression level of the
LETFs – HNF 1, HNF 3, HNF 4 and C/EBP  in
Huh7 cells incubated with HepG2 CM. This was done to
verify whether the decrease of miR-122 in Huh7 cells by
HepG2 was because of a decreased expression of LETFs.
Low miR-122 level in hepatic tumours correlates with re-
duced expression of these liver-specific transcription fac-
tors, suggesting a regulatory role for these proteins on hep-
atic miR-122 level (19,25,40). Real-time analysis confirmed
reduced expression of several of these LETFs accompanied
by reduced miR-122 expression in Huh7 cells treated with
HepG2 CM (Figure 3I). CHIP-PCR analysis using anti-
bodies against RNA polymerase II, HNF1, HNF3 and
HNF4 (36,41) revealed reduced binding of the miR-122
promoter element by these transcription factors in Huh7
cells treated with HepG2 CM (Figure 3J). Therefore, it is
evident that factor(s) present in HepG2 CM are able to
cause reduction in the levels of miR-122 and pre-miR-122
in Huh7 cells by reducing LETF activity and their binding
to miR-122 promoter.
HepG2 secreted factors increase mTOR signalling in neigh-
bouring hepatic cells
Downregulation of miR-122 is a characteristic feature of
humanHCC and this is accompanied with the deregulation
of mTOR signalling which plays a pivotal role in the patho-
genesis of HCC (42–44). There is also evidence that the p38
MAPK cascade is downregulated in human HCCs that ac-
counts, in part, for the resistance of cells to apoptosis, lead-
ing to unrestricted growth of human HCCs (45,46). Also,
the activity of ERK1/2 is significantly higher in human
HCCs than in adjacent nontumorous lesions (46). Huh7
cells in the presence of HepG2 CM demonstrate reduced
miR-122 expression along with an increased growth rate
(Figure 2A) To identify the nature of the factor responsible
for downregulation of miR-122 in Huh7 cells, the status of
different intracellular signals in Huh7 cells incubated with
HepG2 CM was checked. As a control, Huh7 cells were in-
cubated for the same duration with Huh7 CM. Upon incu-
bation with HepG2 CM, there was an increase in the phos-
phorylation of mTORwith respect to control. This increase
was coupled with an elevation in the levels of phosphor-p70
S6 kinase, a downstream target of mTOR. On the other
hand, phosphorylated p38 MAPK levels appeared to de-
crease in HepG2 treated Huh7 cells as compared to con-
trol. There was also an increase in the level of phospho-
rylated ERK1/2 (Figure 4A). This increase in the phos-
phorylated form of various proteins of the AKT/mTOR
pathway was found to be reversed in the presence of 50
nM of Rapamycin, the mTOR inhibitor (Figure 4B). In the
presence of Rapamycin, the HepG2 CM induced decreased
miR-122 activity in Huh7 was also found to be reversed
thereby indicating that the decreased expression ofmiR-122
in Huh7 cells in the presence of HepG2 is mediated by the
Rapamycin sensitive AKT/mTOR signalling pathway (Fig-
ure 4C).
HepG2 secreted IGF1 reduces miR-122 expression and activ-
ity in neighbouring cells
HepG2 cells secrete factors that activate AKT/mTOR and
ERK signalling pathways in the neighbouring Huh7 cells,
concomitant with a corresponding decrease in miR-122 ex-
pression. We attempted to decipher the nature of this se-
creted factor. To determine whether this secreted factor was
exosomal, Huh7 cells were co-cultured with HepG2 cells in
the presence or absence of GW4869. No effect of the drug
on the ability of HepG2 secreted factor to reduce miR-122
level in Huh7 cells was noticed (Figure 5A). Thus the factor
secreted by HepG2 cells, which induces a decrease in miR-
122 expression in Huh7 cells, is likely non-exosomal.
HCC cells are known to express various growth fac-
tors such as Epidermal Growth Factor (EGF), Hepato-
cyte Growth Factor (HGF), Transforming Growth Factor
 (TGF-) and Insulin-like Growth Factor (IGF), which
induce cell proliferation in an autocrine fashion (47). The
receptors of these growth factors are known to activate in-
tracellular signals such as the Raf/MEK/ERK pathway
and the PI3K/AKT/mTOR pathway, which induce pro-
liferation of HCC cells (48). We incubated miR-122 re-
porter transfected Huh7 cells with DMEM containing var-
ious growth factors for 16 h. Luciferase assays revealed that
various concentrations of IGF1 when added to DMEM
lead to a decrease in miR-122 activity in Huh7 cells as com-
pared to control and other growth factor treated Huh7 cells
(Figure 5B). Quantification revealed a corresponding de-
crease inmiR-122 level and activity upon IGF1 treatment of
Huh7 cells (Figure 5C, D and E). No such decrease was ob-
served for two other miRNAs tested in IGF1 treated Huh7
cells, confirming the miRNA specificity of IGF1 (Figure
5F). Similar decrease of miR-122 was also noted in mouse
primary hepatocytes incubated with IGF 1 in culture (Fig-
ure 5G). Pre-miR-122 and mRNA levels of various Hep-
atic Nuclear Factors like HNF1, HNF3, HNF4 and
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Figure 4. HepG2 CM activates mTOR pathway in Huh7 cells. (A) Western blot analysis was done to detect the levels of phosphorylated and nonphos-
phorylated mTOR and its downstream substrate kinases in Huh7 cells incubated with either HepG2 CM or Huh7 CM (control) for 48 h with a change
after every 24 h. Also the levels of phosphorylated ERK and p38 MAPK were detected. (B) Effect of Rapamycin on phosphorylation of mTOR and its
downstream kinases in Huh7 cells incubated with HepG2 CM in absence or in presence of 50 nM Rapamycin. Immunoblotting was done to detect the
effect. (C) Effect of Rapamycin on miR-122 activity change in Huh7 cells transfected with RL reporters and incubated with HepG2 CM in presence or
absence of 50 nM Rapamycin. After 48 h cells were lysed and luciferase activity was measured. Experiments were done in triplicate. Data are presented as
means ±SEM of the Relative fold repression (control mean fold repression = 1) and significance is P = 0.0359.
CEBP were quantified in Huh7 cells treated with IGF1
(Figure 5H). In the presence of IGF1, Huh7 cells showed
decreased pre-miR-122 and lower levels of the HNFs. This
is consistent with the notion that IGF1 inhibits miR-122
expression in Huh7 cells.
Knockdown of Insulin LikeGrowth Factor 1 Receptor in
Huh7 cells by siRNAs resulted in a reversal of the decrease
in both miR-122 activity and level upon incubation with
HepG2 CM. CM from siIGF1 transfected HepG2, in con-
trast to siControl transfected HepG2, was unable to reduce
neither miR-122 activity or level in target Huh7 cells (Fig-
ure 5I and J). It also failed to induce proliferation of neigh-
bouring Huh7 cells in a co-culture of siIGF1 transfected
GFP positive HepG2 and untransfected DsRed express-
ing Huh7 (Supplementary Figure S5B). Similarly, depletion
of IGF1R in Huh7 cells made them immune to HepG2
CMmediated downregulation of miR-122 activity and level
in Huh7 cells (Figure 5I and K). When IGF1-antibody
blocked HepG2 CM was added, there was no inhibitory
effect associated with HepG2 CM on miR-122 activity in
Huh7 cells; rather an increase in miRNA activity was ob-
served (Figure 5I). Therefore, as compared to nIgG,-IGF1
blocked CM showed increased miR-122 activity, suggest-
ing that IGF1 present in HepG2 CM causes inhibition of
miR-122 expression leading to decreased miR-122 activity
in Huh7 cells. Interestingly, treatment with HepG2 CM in-
creases IGF1R expression in target Huh7 cells. IGF1R is a
known target of miR-122 (28) and hence this increase may
possibly be a consequence of the decreasedmiR-122 expres-
sion in Huh7 cells (Figure 5L).
HepG2 cells overcome tumour suppressing effect of exosomal
miR-122 by secreting IGF1
As evidenced from the individual growth rate curves of
mixed cell populations described earlier in Figure 3A, it
seems that when co-cultured, HepG2 and Huh7 cells recip-
rocally regulate each other’s growth. miR-122 is known to
repress genes involved in metastasis, invasion (ADAM10,
ADAM17) and apoptosis (Bcl-w) (26,28,49). Hence, we hy-
pothesized that co-culture of Huh7 with HepG2 cells would
lead to reduced invasion of HepG2 due to transfer of miR-
122 from Huh7. We co-cultured stably transfected DsRed
positive HepG2 cells with Huh7 and determined the per-
centage of invaded HepG2 cells on matrigel. In the pres-
ence of Huh7, HepG2 cells showed reduced invasion. In the
presence of GW4869 which inhibits exosome release, the ef-
fect of Huh7 on HepG2 invasion was reduced and higher
number of HepG2 invaded the matrigel. As expected, co-
culture of DsRed HepG2 with HepG2 overexpressing miR-
122 leads to a reduced number of DsRed cells invading
through the matrigel (Figure 6A and Supplementary Fig-
ure S8). Exosomes from Huh7 also reduced the invasive
ability of HepG2 cells. Huh7 exogeneously expressing pre-
miR-122 leads to a lesser number of DsRed HepG2 cells in-
vading through matrigel than control (Figure 6B and Sup-
plementary Figure S9A). Addition of exosomes fromHuh7
transfected with anti-miR-122 oligonucleotides only par-
tially reversed the effect of Huh7 exosomes. This may have
been because of the reduced transfection efficiency of Huh7
cells which resulted in incomplete inhibition of transferable
miR-122 via exosomes. However, anti-miR-122 oligonu-
cleotides transfected HepG2 cells treated with Huh7 exo-
somes resulted in complete reversal of the reduction in inva-
sive potential observed in the case of anti-let-7a transfected
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HepG2 cells (Figure 6C and Supplementary Figure S9B).
These experiments demonstrate the tumour suppressive and
anti-invasive activity of the transferred miR-122 on target
HepG2 cells.
IGF1 secreted by HepG2 inhibits miR-122 biogenesis in
co-cultured Huh7 cells, and this in turn may be the rea-
son behind the increased growth rate of Huh7 observed in
HepG2 co-cultured cell populations. Huh7 cells in turn ex-
ert a restorative effect on HepG2 by transferring miR-122
to HepG2. Does the secretion of IGF1 from HepG2 have
any effect on this restorative property ofHuh7? CanHepG2
cells circumvent the growth inhibitory effect exerted by the
transferred miR-122 by secreting IGF1? HepG2 cells ex-
pressing GFP were transfected with siRNAs against IGF1
or a control siRNA and were layered on Huh7 cells pre-
seeded onmatrigel. The percentage of invadedGFPpositive
cells was detected.HepG2 cells with compromised IGF1 (si-
IGF1 transfected) showed reduced invasion through Huh7
layered on matrigel than the control siRNA transfected
HepG2 cells (Figure 6D and Supplementary Figure S9C).
Thus, IGF1 released by HepG2 cells enabled the cells to be-
come more invasive in nature through a layer of cells ex-
pressing miR-122.
IGF1 increases proliferation of Huh7 cells
We next examined the phenotypic effect of IGF1 secretion
by HepG2 on Huh7 proliferation. Huh7 cells expressing
GFP were co-cultured with non-transfected Huh7 (control)
or HepG2 cells and the percentage of PCNA and GFP-
positve Huh7 cells co-localizing with DAPI was counted.
In the presence of HepG2, Huh7 cells showed greater num-
ber of PCNA positive cells than control. This effect was
replicated after incubation of Huh7 cells with HepG2 CM
(Figure 6E and F). To determine the role of the secreted
IGF1 in this phenomenon, we incubated GFP transfected
Huh7 cells with exosome depleted CM from Huh7 (con-
trol), HepG2 or exosome depleted Huh7 CM containing
100 ng/ml of IGF1. In the presence of IGF1, Huh7 cells
showed increased proliferation as evidenced by the percent-
age of PCNA positive GFP cells co-localizing with DAPI
(Figure 6G and H).
Co-culture with HepG2 leads to reduced number of
senescent Huh7 cells. The decrease in senescent cell number
was also there after anti-miR-122 expression in Huh7 indi-
cating that the inhibition of miR-122 expression by HepG2
could lead to reduced senescence of Huh7 cells (Figure 6I
and J). HepG2 CM incubated Huh7 cells also exhibited re-
duced -galactosidase staining that suggests less senescence
in presence of an inhibitory factor secreted by HepG2 cells.
The addition of 100 ng/ml of IGF1 reduced the number of
senescentHuh7 cells. Thus IGF1, secreted byHepG2, could
be responsible for the decrease in senescence in HepG2 CM
treated or HepG2 co-cultured Huh7 cells (Figure 6K and
Supplementary Figure S10).
DISCUSSION
In this study, we have established amodel in which cells hav-
ing differentmiRNAprofiles when co-cultured together can
reciprocally regulate each other’s miRNA levels, thereby af-
fecting proliferation and senescence status of both cells. In-
tercellular transfer of miRNAs between cancer and normal
cells has already been reported. Tumour suppressor miR-
NAs are usually downregulated in cancer cells, leading to
tumour progression and metastasis. Past reports along with
the results of this study indicate that cells with downregu-
latedmiRNAs are compensated by the transfer of exosomes
from surrounding cells containing the decreased miRNAs.
However, this method of maintaining homeostasis does not
ultimately stop the progression of cancer. Hence, cancer
cells must have developed a mechanism by which they can
override this suppressive effect. We wanted to examine this
crosstalk between cells and to that purpose developed a co-
culture system involving hepatic cells having differential ex-
pression of the tumour suppressor miR-122. This miRNA
is detected in very low amount in HepG2, whereas its ex-
pression in Huh7 cells is relatively abundant (28,29).
Here we show the exosome mediated transfer of miR-122
from Huh7 to HepG2 cells. The transferred miRNA was
used in gene repression and could change the expression of
various miR-122 regulated physiological genes in the recip-
ient cells. Co-culture with HepG2 also leads to a recipro-
cal decrease in miR-122 level in Huh7 cells. This decrease
appeared to be CM mediated but surprisingly was not ex-
osome driven. Investigation of the signalling pathway in-
volved revealed that incubationwithHepG2CM leads to an
activation of the mTOR signalling pathway indicating the
possible role of a growth factor in the process. Addition of
various growth factors known to be secreted byHepG2 cells
and otherHCCcells lead to the identification of IGF1 as the
candidate growth factor. Antibody inhibition experiments
coupled with siRNA mediated knockdown of IGF1R in
Huh7 cell and IGF1 in HepG2 cells proved the primary in-
volvement of this factor in reduction of miR-122 in Huh7
cells and also in mouse primary hepatocytes.
Addition of Huh7 exosomes resulted in decreased growth
and invasion of the recipient HepG2 cells. This decrease
was only partially reversed when exosomes isolated from
anti-miR-122 oligonucleotide transfected Huh7 cells were
added to HepG2 cells. To determine the efficacy of the anti-
miR-122 transfection in Huh7 cells, Huh7 cells transfected
with anti-miR-122 oligonucleotides were analysed for cel-
lular miR-122 levels (Supplementary Figure S11A and B).
As a control Huh7 cells transfected with LNATM modified
-anti-miR-122 and LNATM-modified anti-miR-128 (con-
trol) oligonucleotides were similarly analysed. This was
done based on previous reports that Locked Nucleic Acids
modified (LNA) antisense oligonucleotides are more effec-
tive than standard 2’-O-methylmodified oligonucleotides in
binding and inhibiting miRNA action in primate, human
and rat liver cells (32,50). 2’-OMe-anti-miR-122 transfected
Huh7 cells showed reduced levels (∼50%) of intracellular
miR-122. This reduction was comparable to that obtained
with LNA-anti-miR-122 oligonucleotides. Further decrease
in miR-122 levels may not have been possible because of the
low transfection efficiency of Huh7 cells which was deter-
mined to be ∼20% (Supplementary figure S11C).
Reduced levels of miR-122 lead to reduced repression of
miR-122 reporters in luciferase assays (Supplementary Fig-
ure S11D). Also Huh7 cells transfected with anti-miR-122
oligos have higher levels of miR-122 targets compared to
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Figure 5. IGF1 secreted by HepG2 reduces activity and expression of miR-122 in Huh7 cells. (A) Effect of GW4869 on transfer of anti-miR-122 signal
from HepG2 to Huh7 cells. HepG2 cells and Huh7 cells were either co-cultured together or mixed after being cultured separately for 48 h in presence
and in absence of GW4869. Real-time quantification of miR-122 was then done to detect the level of miR-122 in both control and co-cultured samples in
presence or absence of GW4869. Data represents three independent experiments with qPCR for each experiment being conducted in triplicate. P values
were calculated by paired t test. (B) Effect of different growth factors on miR-122 activity in Huh7 cells. Huh7 cells transfected with RL reporters were
incubated for indicated concentrations (ng/ml) of Epidermal Growth Factor (EGF), Hepatocyte Growth Factor (HGF), Transforming Growth Factor 
(TGF-), Insulin-like Growth Facto1 (IGF1) and Insulin-like Growth Factor 2 (IGF2) overnight in DMEM and luciferase activities were measured. Fold
repression was estimated by dividing the normalized RL levels in RL-con and RL-per-miR-122 expressing cells. Relative fold repression was determined by
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control (Supplementary Figure S11E and F). The reduced
level of intracellular miR-122 is also translated into re-
duced levels of exosomal miR-122 released from anti-miR-
122 oligonucleotide (both 2’-O-methyl and LNA modified)
transfected cells (Supplementary figure S11G andH). How-
ever, anti-miR-122 treatment does not totally reduce miR-
122 in exosomes. It may be argued that the remaining resid-
ual exosomal miR-122 has an effect on the recipient HepG2
cells and thus cause only partial reversal of the reduction in
colony formation and invasion as shown in Figures 2C and
6B. Also, Figure 2C describes an experiment where HepG2
cells are incubated with exosomes from Huh7 for 7 days
with changes after every 48 h. It may be hypothesized that
the residual exosomal miR-122 in Huh7 transfected with
anti-miR-122 are transferred to HepG2 during the longer
incubation time involved and restore miR-122 level to an
extent sufficient to observe the effect.
The IGF axis is a complex signalling network that is in-
volved in many physiological and pathological processes
such as mitogenesis, angiogenesis, transformation, differen-
tiation, tissue homeostasis, anti-apoptosis and cell motility
(51). Alterations in this signalling axis have been described
in human hepatocarcinogenesis. In HCC, a decreased tissue
expression of IGF2 and an increased expression of IGF1
receptor (IGF1R) have been reported (52). However, eleva-
tions in the serum level of IGF1 are correlated with an in-
creased risk for developing breast, colon, prostrate and lung
cancer in mouse models (53–55). Thus the role of IGF1 in
the development of hepatocarcinogenesis, at least in the ini-
tial stages, cannot be ruled out.
The keymolecules of this network are the peptide-ligands
IGF1 and IGF2 and the receptors IGF1R, IGF2R and in-
sulin receptor (INSR) (56). The IGF1R binds IGF1 and
IGF2 with high affinity and insulin with very low affinity,
whereas the INSR binds insulin with high affinity.
IGF1R and INSR activate multiple signalling cas-
cades upon ligand binding. The pathways activated
are mainly the Ras-Raf-ERK signalling pathway and
the phosphatidylinositol-3-kinase/AKT (PI3K/AKT) sig-
nalling pathway. These pathways in turn activate multi-
ple signalling cascades affecting cell proliferation, anti-
apoptosis, differentiation, tissue homeostasis (Ras-Raf-
ERK) as well as cell survival, metabolic actions, anti-
apoptosis and differentiation (PI3K/AKT) (57). IGF1R is
found overexpressed in many types of cancer cells and is up-
regulated in primary human HCCs. It has a miR-122 bind-
ing site in its 3’UTR and was shown by Bai et al. to be a
target of miR-122. miR-122 and Igf1r were found to be re-
ciprocally regulated in primary human HCCs (28).
Huh7 cells incubated with HepG2 CM show downregu-
lated expression of miR-122. This is accompanied by an up-
regulation of IGF1R mRNA. This may serve as a positive
feedbackmechanism in which the IGF1 induced downregu-
lation ofmiR-122 is further enhanced because of the accom-
panying upregulation of IGF1R. Thus, we may hypothesize
that IGF1 secreted by HCC cells serves to downregulate
miR-122 in the surrounding normal cells and causes tumour
progression. This study illustrates a mechanism by which
cancer progresses and reinforces the suitability of IGF1R
as a therapeutic potential in HCC. Interestingly, IGF1 ex-
pression in HepG2 cells is decreased upon treatment with
miR-122 containing Huh7 exosomes. In this context, there
seems to be a reciprocal relationship between miR-122 and
IGF1 expression (Supplementary Figure S12).
The in vivo situation in this context is yet to be deter-
mined. It would be interesting to speculate that the exo-
somal delivery of miR-122 containing exosomes between
hepatic cells in liver tissue may serve as a mechanism for
maintaining homeostasis of tissue miRNA. Various envi-
ronmental and genetic factors contribute to HCC develop-
ment. Hepatocarcinogenesis is a step wise process during
which multiple genes are altered. The unbalanced expres-
sion ofmiR-122 during the initial steps of liver cancer devel-
opment may be compensated by exosomal transfer of miR-
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setting the repression level of control as 1. (C, D) Effect of IGF1 on miR-122 activity (C) and Level (D) in Huh7 cells. Cells were incubated with exosome
depleted Huh7 CM alone or supplemented with 100 ng/ml IGFI for 72 h with fresh changes after every 36 h. HepG2 CM was used as a positive control.
(E) Dose response curve to determine the effect of various concentrations of recombinant IGF1 (ng/ml) on the miR-122 level of Huh7 cells. Huh7 cells
were incubated for 24 h with DMEM containing IGF1 (0–50 ng/ml). Total RNA was extracted from the cells and qPCR was done to determine the
miR-122 level. We found that the decrease in miR-122 level starts from 5 ng/ml of IGF1. For panel C experiments were performed in triplicate and P
value was calculated by using unpaired t test. For panels D and E data represents four independent experiments with qPCR for each experiment being
conducted in triplicate. P values were calculated by paired t test. (F) miR-24 and let-7a level change detected by real-time quantification in Huh7 cells
treated with IGF1. Data represents three independent experiments with qPCR for each experiment being conducted in triplicate. P values were calculated
by paired t test. (G) Effect of IGF1 on miR-122 level in primary mouse hepatocytes treated with IGF1. Data represents four independent experiments
with qPCR for each experiment being conducted in triplicate. P values were calculated by paired t test. (H) Quantification of pre-miR-122, and other
hepatic nuclear factor expression in Huh7 cells incubated for 72 h either with HepG2 CM or exosome depleted Huh7 CM containing 0 and 50 ng/ml of
IGF1. Data represents four independent experiments with qPCR for each experiment being conducted in triplicate. P values were calculated by paired
t test. (I) Effect of IGF1 depletion in HepG2 or IGF1R depletion in Huh7 on miR-122 activity in Huh7 cells in presence of HepG2 CM. Huh7 cells
(control or IGF1R depleted), expressing miR-122 RL reporter, were incubated with CM from normal or IGF1 depleted HepG2 for 72 h to determine
the specificity of IGF1 to decrease miR-122 activity in Huh7 cells. For control experiments, non-target siRNA was used. Incubation of HepG2 CM with
IGF1 antibody removed the anti-miR-122 activity. nIgG was used as a control. Fold repression was estimated by dividing the normalized RL levels in
RL-con and RL-per-miR-122 expressing cells. Relative fold repression was determined by taking the control as 1 and expressing repression values relative
to 1. Experiments were performed in triplicate and P value was calculated by using paired t test. (J) Effect of IGF1 depletion on miR-122 level in Huh7
cells incubated with CM fromHepG2 cells transfected with a non-target or IGF1 specific siRNAs. The miR-122 level of the cells was detected by RT-PCR.
Data represents five independent experiments with qPCR for each experiment being conducted in triplicate. P values were calculated by paired t test. (K)
miR-122 level in Huh7 cells depleted for IGF1R (siIGF1R transfected) against control siRNA transfected cells in presence of HepG2 CM. Cellular miR-
122 levels were quantified by RT-PCR. Data represents three independent experiments with qPCR for each experiment being conducted in triplicate. P
values were calculated by paired t test. (L) Effect of HepG2 CM on IGFR1R expression in Huh7 cells. Huh7 cells incubated for 72 h with HepG2 CMwere
analysed for IGF1R mRNA levels by qRT-PCR. Normalization was done by 18S rRNA. Data represents three independent experiments with qPCR for
each experiment being conducted in triplicate. P values were calculated by paired t test. All data is represented as mean ±SEM from multiple independent
experiments. ns: non-significant, *P < 0.05, **P < 0.01 and ***P < 0.001.
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Figure 6. HepG2 cells overcome the tumour suppressive effect of miR-122 containing exosomes by secreting IGF1. (A) Effect of co-culture with miR-122
expressing cells onmatrigel invasion properties of HepG2. DsRed expressingHepG2were co-cultured with HepG2 (control) or Huh7 cells (with or without
GW4869 treatment) on matrigel coated polycarbonate membrane having a pore size of 8 m. After 48 h, cells were fixed, and the number of cells which
had invaded through the matrigel layer to the outer side was determined. HepG2 cells expressing miR-122 was used as a positive control. DAPI stained the
nucleus and the percentage of invaded DsRed cells was determined by counting the number of DAPI and DsRed double positive cells. Results represent
data from ≥ 5 independent fields taken from two independent experiments. (B) Effect of miR-122 containing exosome treatment on matrigel invasion
properties of HepG2 cells. HepG2 cells stably expressing DsRed were incubated with exosomes isolated either from HepG2, Huh7, anti-miR-122 or let-7a
expressing Huh7, or from Huh7 exogenously expressing miR-122. The number of DsRed cells invaded through matrigel was counted. (C) Experiments
similar to described in B were done with HepG2 cells pre-transfected with anti-miR-122 and anti-let-7a oligos. Results represent data from≥6 independent
fields taken from two independent experiments. (D) Effect of IGF1 depletion on invasive property of HepG2 co-cultured with miR-122 expressing Huh7
cells. HepG2 cells expressing GFP were transfected either with siRNAs against IGF1 or with a control siRNA. Cells were seeded onto Huh7 cells layered
on matrigel coated polycarbonate membranes having pore sizes of 8 m. The number of invaded GFP positive cells colocalizing with DAPI was counted
after 24 h of co-culture. Results represent data from ≥15 independent fields taken from two independent experiments. (E, F) Effect of HepG2 co-culture
or HepG2 CM treatment on proliferation of Huh7 cells. GFP transfected Huh7 cells were co-cultured with nontransfected Huh7 (control) or HepG2 cells
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122 from normal to cancer cells. However, upregulation of
growth factors and their receptors, like IGF1R, may con-
tribute to crossing the final hurdle towards cancer develop-
ment. Additionally, miR-122-mediated downregulation of
IGF1 release by hepatic cells may serve as another poten-
tial therapeutic avenue.
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